semaglutide adolescent obesity trial 2022 as a GLP-1 Agonist: A Breakthrough in Treatment Prescriptions for Obesity Medications Among

One study compared elderly patients (mean age 65 years) with subclinical hyperthyroidism to euthyroid subjects for 2 years

Coordinated care between prescribing clinician and GP ensures safe management of both conditions with appropriate monitoring and dose adjustments

Data on patients prescribed oral semaglutide are presented as a single cohort

The FDA has also warned patients with the following conditions to take this drug with caution: gastroparesis, pancreatitis, and renal impairment

CI: Confidence interval

Speak with your healthcare professional if you have any questions or are unsure if your medication is safe to use.